78.51 0.00 (0.00%)
After hours: 5:21PM EDT
|Bid||78.46 x 1000|
|Ask||78.51 x 900|
|Day's range||78.36 - 80.37|
|52-week range||57.00 - 89.30|
|Beta (3Y monthly)||0.93|
|PE ratio (TTM)||55.25|
|Earnings date||29 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||93.59|
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
Incyte Corporation announced today that it will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am / 10:35 am in Scottsdale, Arizona.
Solid progress in its expansion areas of Software and Enterprise and excellent momentum in IP Routing business are likely to have benefited Nokia's (NOK) third-quarter 2019 financial results.
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Incyte Corporation (INCY) today announced positive results from the Novartis-sponsored pivotal Phase 3 REACH2 study evaluating ruxolitinib (Jakafi®) in patients with steroid-refractory acute graft-versus-host disease (GVHD). The study met its primary endpoint of improving overall response rate (ORR) at Day 28 with ruxolitinib treatment compared to best available therapy.
The NDA for Blueprint Medicines' (BPMC) lead candidate avapritinib is currently under review in the United States. Heavy reliance on partners for collaboration revenues remains a concern.
- Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream
Seattle Genetics (SGEN) doses the first patient in the phase III HER2CLIMB-02 study on tucatinib in combination with Roche's Kadcyla for treating advanced/metastatic HER2-positive breast cancer.
bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.
Incyte Corporation announced today that it has scheduled its third quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2019.
The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.
The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.
WILMINGTON, Del.-- -- Data presented at ESMO support the planned submission of a New Drug Application to the U.S. Food and Drug Administration for pemigatinib before the end of 2019 Investor conference call and webcast scheduled for today, September 27, at 5:00 p.m. CEST Sixth paragraph, fourth sentence of release should read: Serous retinal detachment was observed in 4 percent of patients with none ...
Incyte (INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo. “Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group Vice President and Head of Inflammation and Autoimmunity Group, Incyte.